Sensei Biotherapeutics, Inc. (SNSE)

Significant stock events in the past six months include the announcement of a strategic review and discontinuation of solnerstotug development on October 30, 2025, and the report of third-quarter 2025 financial results on November 14, 2025. On February 18, 2026, the company announced the acquisition of Faeth Therapeutics and a $200 million private placement, leading to a significant stock price increase. Inducement grants of stock options to new employees were announced on February 19, 2026, and March 17, 2026. The company reported full-year 2025 financial results and provided a corporate update on March 30, 2026. Sensei Biotherapeutics presented at the 25th Annual Needham Virtual Healthcare Conference on April 9, 2026, and dosed the first patient in its Phase 1b/2 trial of PIKTOR on May 5, 2026.

As a clinical-stage biotechnology company with products in development and not yet on the market, there is no information indicating demand seasonality for Sensei Biotherapeutics, Inc.'s products or services.

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing next-generation cancer therapeutics, operating within the Healthcare sector and Biotechnology industry. The company utilizes its Tumor Microenvironment Activated biologics (TMAb) platform to develop conditionally active therapeutics. Its major product candidates include PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway, Solnerstotug (formerly SNS-101), a conditionally active antibody designed to block the VISTA checkpoint (development discontinued in October 2025), SNS-102 and SNS-103, conditionally active monoclonal antibodies in early development stages for solid tumors, and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

Sensei Biotherapeutics, Inc. is headquartered in Rockville, Maryland, with an additional location in Boston, Massachusetts, and operates within the United States market.

Information specifically detailing Sensei Biotherapeutics, Inc.'s brand reputation or events that have explicitly affected it in the past year is not readily available. The news primarily focuses on corporate strategy, clinical trial progress, financial results, and acquisitions.

Sensei Biotherapeutics, Inc. has both institutional and individual owners. As of May 7, 2026, there were 12 institutional owners and shareholders holding a total of 52,776 shares, including Ikarian Capital, LLC, and Catalio Capital Management, LP. Significant individual insider shareholders include James Peyer, Hs Investments I LP, and Thomas G. Ricks.